目的 探討神經(jīng)節(jié)苷脂與醒腦靜聯(lián)合應(yīng)用對急性腦卒中患者實驗室指標(biāo)及預(yù)后的影響。方法 以開封市第二人民醫(yī)院2013年9月—2017年6月130例急性腦卒中患者為研究對象，采用隨機數(shù)字表法將入選者分為對照組和觀察組，每組65例。對照組在常規(guī)治療基礎(chǔ)上將10~20 mL醒腦靜注射液加入到0.9%的生理鹽水250 mL中靜脈滴注，1次/d。觀察組在對照組的基礎(chǔ)上將40 mg神經(jīng)節(jié)苷脂鈉注射液加入到0.9%的生理鹽水250 mL中靜脈滴注，1次/d。兩組均治療1個月。比較兩組患者的臨床療效、治療前后神經(jīng)功能、認(rèn)知功能、日常生活能力、血清腫瘤壞死因子-α（TNF-α）、白介素-6（IL-6）水平變化及不良反應(yīng)發(fā)生情況。結(jié)果 觀察組及對照組患者治療總有效率分別為90.77%、73.85%，觀察組明顯高于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療前兩組患者神經(jīng)功能缺損程度（NIHSS）、簡易智能狀態(tài)檢查量表（3MS）、巴氏指數(shù)（BI）評分及血清TNF-α、IL-6水平比較無顯著性差異；治療后兩組患者NIHSS評分及血清TNF-α、IL-6水平均明顯降低，3MS、BI評分明顯升高，同組治療前后比較存在顯著性差異（P<0.05）；治療后觀察組患者NIHSS、3MS、BI評分及及血清TNF-α、IL-6水平改善情況均顯著優(yōu)于對照組，兩組比較存在顯著性差異（P<0.05）。觀察組及對照組患者各不良反應(yīng)的發(fā)生率比較無顯著性差異。結(jié)論 神經(jīng)節(jié)苷脂與醒腦靜聯(lián)合應(yīng)用可有效改善患者的神經(jīng)功能、認(rèn)知功能及日常生活能力，提高治療效果，降低血清炎性因子水平，且不增加不良反應(yīng)，在急性腦卒中的治療中具有重要應(yīng)用價值。

Objective To explore improvements of laboratory indicators and prognosis in patients with Acute stroke treated with ganglioside combined with xingnaojing.Methods 130 Patients with Acute stroke of The Second People's Hospital of Kaifeng City were selected as the subjects from September 2013 to June 2017. According to random number table method were divided into the control group and study group with 65 cases in each. The control group patients were treated with Xingnaojing, the experimental group on the basis of this combination of Ganglioside. Compared the two groups of patients with clinical effect, Neurological function, cognitive function, daily living ability (ADL), Serum TNF-α, IL-6 levels changing and incidence of adverse reactions before and after treatment.Results The total effective rate in the experimental group were obviously higher than those in the control group (P<0.05). Before treatment, there was no significant difference in NIHSS, 3MS, BI score and serum TNF-α, IL-6 levels between the two groups. After treatment, NIHSS score and serum TNF-α, IL-6 levels were significantly decreased, while 3MS, BI scores were significantly increased, there were significant differences between before and after (P<0.05). The study group of NIHSS, 3MS, BI scores and serum TNF-α, IL-6 levels were significantly better than that of the control group and there was significant difference (P<0.05). The incidence of adverse reactions had no statistically significant differences between the two groups.Conclusions Ganglioside combined with Xingnaojing in treating Acute stroke can effectively improve neurological function, cognitive function, daily living ability, enhance the therapeutic effect, reduce the level of serum inflammatory factors and don't increase the adverse reactions, which has important application value.